Krishna Institute of Medical Sciences

As of 2026-11-06, KIMS trades at ₹728.00, positioned near the upper end of its 20-day range (+79.5%) but roughly mid-range over the last year (+53.9%). The daily trend is established and bullish, with price holding above the 20-period EMA and SMA while remaining below the 50-period and 200-period moving averages. ADX stands at 26.26, indicating defined directional movement, though the monthly trend remains weak (ADX 13.93). Recent activity shows a high-participation downward anomaly on 2026-11-06 (-0.4% return) and an active monthly 'Inside Bar' pattern, suggesting consolidation. Immediate resistance lies at ₹733.10 (pivot), followed by highs at ₹743.70 and ₹754.19. Support is found at ₹720.45, with deeper levels at ₹709.85 and ₹697.20. The stock carries an annualized volatility of +31.9% and a current drawdown of -14.4%. A break above ₹733.10 could signal renewed upside momentum, while a close below ₹720.45 may invalidate the short-term bullish structure.

Krishna Institute of Medical Sciences (KIMS) reported strong top-line growth for the second quarter, with revenue jumping 40% to ₹1,344 crore and consolidated net profit rising 12% to ₹75 crore. Despite this volume expansion, the company’s EBITDA margin narrowed to 19.4%, indicating that cost structures or pricing pressures offset some of the revenue gains. To support future scale, KIMS doubled the capacity of its Saveera Hospital in Anantapur, Andhra Pradesh, from 250 to 500 beds, adding specialized oncology and mother-and-child care infrastructure. Corporate governance was also reinforced through the board’s approval to merge KIMS Hospitals Private Limited with the parent entity and the reappointment of key leadership on five-year terms. On the analyst front, Prabhudas Lilladher issued a 'Buy' recommendation with a target price of ₹800 as of November 6, 2026.

Krishna Institute of Medical Sciences (KIMS) disclosed the audio recording of its Analyst/Investor Meet for FY 26-27 on November 5, 2026. The call concluded at 11:00:00 IST, with the recording uploaded to the company website later that day. This filing is a routine procedural disclosure and reports no substantive business decisions or operational outcomes from the meeting itself.

Separately, on the same date, Prabhudas Lilladher issued a 'Buy' recommendation for KIMS shares, setting a target price of ₹800. While this provides an external valuation perspective, it represents analyst opinion rather than a corporate action or financial result reported by the company.

Krishna Institute of Medical Sciences Limited (KIMS) reported unaudited consolidated financial results for Q2 FY27 (ended September 30, 2026), alongside a board-approved corporate restructuring. Financially, the company posted total income of ₹1,363 crore, with an EBITDA of ₹278.9 crore and PAT of ₹76 crore. An accompanying investor presentation detailed Group Operating Revenue at ₹1,344.4 million for Q2, marking a 39.9% quarter-on-quarter increase, supported by EBITDA margins of 18.7% and PAT of ₹1,025 million. Operational activity expanded significantly, with In-Patient (IP) volumes rising 12.7% to 122,000 and Out-Patient (OP) volumes growing 11.0% to 1,390,000. The Board also approved the amalgamation of its wholly-owned subsidiary, KIMS Hospitals Private Limited, into the holding company to simplify structure and achieve operational efficiencies; this related-party transaction is exempt from shareholder approval. Strategic expansion continues with the addition of a third hospital in Palakkad, Kerala, and a pipeline of 700+ beds through greenfield and acquisition opportunities across Telangana, Andhra Pradesh, Maharashtra, Karnataka, and Kerala.

Krishna Institute of Medical Sciences (KIMS) is executing a high-growth expansion phase, evidenced by robust revenue momentum offsetting near-term earnings compression. For Q2 FY2026-27, revenue from operations rose sequentially to ₹1,344 crore, while net profit more than doubled to ₹74.6 crore compared to Q1’s ₹37.4 crore. This sequential improvement coincided with a reduction in finance costs from ₹83.4 crore to ₹65.5 crore, suggesting improved debt servicing efficiency or lower borrowing rates as the company scales.

However, the broader annual trajectory reveals significant margin pressure. While sales grew 28% year-on-year to ₹3,905 crore in FY2026, net profit fell sharply to ₹242 crore from ₹415 crore in FY2025. Interest expenses nearly doubled to ₹215 crore, and depreciation surged to ₹66 crore in the Sep 2025 quarter alone, reflecting the heavy capital expenditure cycle. The balance sheet confirms this aggressive build-out: fixed assets jumped to ₹5,710 crore, borrowings increased to ₹4,253 crore, and working capital days deteriorated to 52 days. Cash conversion quality has also weakened, with CFO/EBITDA dropping from 102% in Mar 2024 to 81% in Mar 2026. Despite these headwinds, return on capital employed remains positive at 10%, though down from 17% three years ago.

Krishna Institute of Medical Sciences (KIMS) presents a conditional upside case anchored by robust operational expansion and strong top-line growth, despite near-term margin compression. The company doubled the capacity of its KIMS Saveera Hospital in Anantapur to 500 beds, adding specialized oncology and mother-and-child blocks, which signals aggressive geographic and service-line penetration. Financially, Q2 revenue surged 40% year-on-year to ₹1,344 crore, with net profit rising 12% to ₹75 crore. While EBITDA margins narrowed to 19.4%, likely due to the ramp-up costs associated with new infrastructure, the substantial revenue jump indicates successful demand absorption. Corporate governance stability is reinforced by the board’s approval of the merger with KIMS Hospitals Private Limited and the reappointment of key leadership for five-year terms. Technically, the stock trades at ₹728.0 on the NSE, sitting just below immediate resistance levels, while maintaining a bullish monthly supertrend direction. This constructive setup suggests that if the company can stabilize or expand margins as the new capacities come online, the current valuation may reflect a temporary dislocation rather than fundamental weakness.

Krishna Institute of Medical Sciences (KIMS) faces a divergence between strong top-line growth and deteriorating profitability, alongside technical weakness in the stock. While Q2 revenue surged 40% to ₹1,344 crore, the EBITDA margin narrowed to 19.4%, indicating that cost pressures or operational inefficiencies are outpacing sales expansion despite a 12% rise in net profit to ₹75 crore. Technically, the stock is trading at ₹728.00 with a significant current drawdown of -14.4% from recent peaks, having experienced a maximum drawdown of -26.3%. The weekly trend is bearish, and the stock has declined 10.0% over the last three months, contrasting with an 18.2% year-to-date gain. High annualized volatility of 31.9% suggests elevated price risk for investors.